
|Videos|February 18, 2014
The Utility of CAR-Modified T Cells in Myeloid Malignancies
Author(s)Renier J. Brentjens, MD, PhD
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the utility of CAR-modified T cells in myeloid malignancies.
Advertisement
Clinical Pearls
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the utility of CAR-modified T cells in myeloid malignancies.
- Ideally, CAR-modified T cells should have utility in myeloid malignancies
- Identifying a target for CAR-modified T cells to recognize remains a challenge
- There is always the danger of targeting a protein expressed on normal tissues or stem cells
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
5



















